Annexon, Inc. Share Price & Technical Analysis
ANNX · $5.31 (-2.39%)
Healthcare / Biotechnology
$5.31
-2.39%
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-9% return in May, -11% avg return in past 3 year May month.
6% return in 2026, 35% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 22% | -8% | -2% | 4% | -9% | – | – | – | – | – | – | – | 6% |
| 25 | -27% | -32% | -27% | 0% | 5% | 14% | 0% | -9% | 43% | 7% | 41% | 14% | 29% |
| 24 | -7% | 33% | 16% | -35% | 4% | 0% | 28% | -11% | 5% | 24% | -27% | -6% | 25% |
| 23 | 37% | -26% | -28% | 39% | -43% | 17% | 0% | -20% | -14% | 0% | 9% | 80% | 49% |
| 22 | -35% | -36% | -44% | -7% | 24% | 19% | 32% | 18% | 9% | -24% | 13% | -5% | -38% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$901.13M
P/E ratio
—
52W high
$7.18
52W low
$1.85
Volume
21,80,186
Beta
1.22
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Annexon, Inc. share price today?
- Annexon, Inc. (ANNX) last traded around $5.31 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ANNX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ANNX. Download the app for real-time alerts.
- How can I analyze Annexon, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.